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Abstract
While normal cells in the human breast are organized into acinar structures, disruption of the acinar architecture is
a hallmark of cancer. In a three-dimensional model of morphogenesis, we show that down-regulation of the matrix-
associated tumor suppressor protein CCN6 (WNT1-inducible-signaling pathway protein 3) disrupts breast epithelial
cell polarity and organization into acini through up-regulation of the type III transforming growth factor–β receptor
(TβRIII or betaglycan). Down-regulation of CCN6 in benign breast cells led to loss of tissue polarity and resulted
in cellular disorganization with loss of α6 integrin–rich basement membrane and the basolateral polarity protein
E-cadherin. Silencing of TβRIII with shRNA and siRNA rescued the ability of breast epithelial cells to form polarized
acinar structures with reduced matrix invasion and restored the correct expression of α6 integrin and E-cadherin.
Conversely, CCN6 overexpression in aggressive breast cancer cells reduced TβRIII in vitro and in a xenograft model
of CCN6 overexpression. The relevance of our studies to human breast cancer is highlighted by the finding that CCN6
protein levels are inversely associated with TβRIII protein in 64% of invasive breast carcinomas. These results reveal a
novel function of the matricellular protein CCN6 and establish a mechanistic link between CCN6 and TβRIII in main-
taining acinar organization in the breast.
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Introduction
The functional unit of the normal human breast is the terminal duct
lobular unit, composed of a small duct that ends in acinar structures
[1]. In the acini, normal breast cells are organized with the apical cyto-
plasm toward a central lumen and the basal portion toward the base-
ment membrane. The normal acinar organization is disrupted in
invasive carcinoma. Cancer cells form disorganized clusters and anas-
tomosing structures characterized by loss of cellular polarization and a
haphazard invasive pattern [1]. Although the morphologic differences
between normal acini and invasive carcinoma are well delineated, the
major regulators of this transition need to be elucidated.
The matricellular protein CCN6 (also known as WNT1-inducible-
signaling pathway protein 3) was found to have tumor suppressor
functions in breast cancer [2–4]. Our laboratory has demonstrated
that CCN6 is secreted from epithelial cells in the breast and decreases
activation of the insulin-like growth factor-1 (IGF-1) and bone
morphogenetic protein (BMP) signaling pathways in breast cancer
[5–7]. Recently, it was reported that down-regulation of CCN6 in
benign breast cells induces an epithelial-to-mesenchymal transition
and invasion [3]. The function of CCN6 in normal acinar organization
is unknown.
The type III transforming growth factor–β (TGF-β) receptor
(TβRIII/betaglycan) is a transmembrane glycoprotein originally identi-
fied as a non-signaling co-receptor for TGF-β, with a main function of
presenting TGF-β ligands to the TGF-β receptors [8–12]. Subsequent
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studies determined that TβRIII regulates TGF-β signaling independent
of its ligand presentation role [9,12,13]. In cancer, while TβRIII has
tumor suppressor functions [14–16], it has been reported to promote
cancer progression [17]. These data underscore the need to further
define the function of TβRIII in normal breast and in breast cancer.
In this study, we hypothesized that CCN6 is a key determinant of
acinar organization and sought to understand the underlying mech-
anism. Using benign human mammary epithelial (HME) cells and
breast cancer cells, we demonstrate that CCN6 regulates acinar orga-
nization through TβRIII. In three-dimensional (3D) cultures, CCN6
blockade is sufficient to disrupt acinar organization and cell polarity
and to induce TβRIII up-regulation. Silencing of TβRIII using siRNA
and shRNA led to phenotypic reversion with correct apical-basal po-
larity. Conversely, ectopic expression of CCN6 in breast cancer cells
reduced TβRIII in 3D and in murine primary tumors and distant
metastasis. In clinical specimens from patients with breast cancer,
CCN6 expression is inversely associated with TβRIII protein levels,
providing in vivo relevance to the functional results. These data identify
a novel axis of cell regulation relevant to breast tumorigenesis by linking
a matrix protein with control of acinar organization in the breast.
Materials and Methods
Cell Culture
HME cells were obtained from Dr Ethier (Karmanos Cancer
Institute). Cell lines were authenticated by morphology and growth
characteristics and tested for mycoplasma. HME and their stable cell
lines were selected and cultured as previously reported [2,3]. MDA-
MB-231 cells were purchased form ATCC (Manassas, VA) and main-
tained following the manufacturer’s instructions.
Development of Overexpression and Knockdown Cells
The generation of CCN6-Flag overexpressing MDA-MB-231
cells and CCN6 knockdown (CCN6 KD) HME cells have been
previously reported [2,3,7]. Briefly, to generate CCN6 and TβRIII
double stable knockdowns in HME cells, cells were transduced
with specific lentivirus and selected by puromycin (5 μg/ml; Sigma,
St Louis, MO), at 37°C under 5% CO2. Lentivirus was packaged at
the University of Michigan Vector Core (specific targeting shRNA
of TβRIII: TRCN0000033429, Open Biosystems (Lafayette, CO);
specific targeting shRNA of CCN6: TRCN0000033361, Sigma).
Validated On-Target siRNA were purchased from Dharmacon
Thermo Scientific (Chicago, IL; Scrambled siRNA: D-001810-10-
05; TβRIII siRNA: L-010545-00). Cells were split into complete
medium for 24 hours. siRNA oligos were transfected into subcon-
fluent cells with DharmaFECT 1 Transfection reagent (Dharmacon
Thermo Scientific) in accordance with the manufacturer’s instruc-
tions. After 48 hours of growth in complete media, cells were har-
vested by trypsinization and used for subsequent experiments
described below.
3D Cultures and Immunocytochemistry
Cells were grown on top of growth factor reduced matrigel (Cat.
No. 354230; BD Transduction, Bedford, MA) for 15 days following
published protocols [18]. Phase contrast images were taken on a Leica
inverted microscope. Immunocytochemical analysis was carried out as
reported [18]. Briefly, cells were fixed with freshly prepared 2% para-
formaldehyde for 20 minutes at room temperature followed by per-
meabilization with phosphate-buffered saline (PBS) containing 0.5%
Triton X-100 for 10 minutes at 4°C. The acinar-like structures were
rinsed three times with phosphate-buffered saline/glycine for 10 to
15 minutes per wash at room temperature before incubating for pri-
mary block with immunofluorescence (IF) buffer (130 mM NaCl,
7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA,
0.2% Triton X-100, and 0.05% Tween-20) + 10% goat serum for
1 to 1.5 hours at room temperature, followed by secondary block
[IF buffer + 10% goat serum + 20 μg/ml goat anti-mouse Fab frag-
ment (No. 15-006-006; Jackson ImmunoResearch, West Grove,
PA)] for 30 to 40 minutes. Primary antibody incubation was done
overnight in the secondary block solution at 4°C. The cells were
washed three times for 20 minutes with IF buffer at room tempera-
ture with gentle rocking. Secondary antibody incubation was done
with fluorescent-conjugated secondary antibody in IF buffer + 10%
goat serum for 40 to 50 minutes at room temperature. We used Alexa-
conjugated antibodies from Molecular Probes (Grand Island, NY) at
1:200. The fluorochromes used were 4′,6-diamidino-2-phenylindole
(DAPI), Alexa 488, 568, 594, 633, and 680. After washing three
times for 15 to 20 minutes each, the cells were mounted with prolong
gold anti-fade reagent with DAPI (No. P36931; Molecular Probes,
Invitrogen, Grand Island, NY).
Immunoblot Analyses
Cell lysates were collected using NP-40 lysis buffer containing
50 mM Tris-HCl, (pH 7.4), 1% NP-40, and a mixture of prote-
ase inhibitors (Roche, Indianapolis, IN). Samples were boiled in
1× sodium dodecyl sulfate loading buffer, separated by sodium do-
decyl sulfate–polyacrylamide gel electrophoresis gels, and transferred
onto a nitrocellulose membrane. For immunoblot analysis, nitro-
cellulose membranes were blocked with 5% nonfat dry milk and
were incubated with corresponding primary antibodies at 4°C over-
night. Immunoblot signals were visualized by a chemiluminescence
system as described by the manufacturer (Amersham Biosciences,
Piscataway, NJ). Blots were reprobed with β-actin to confirm the equal
loading of samples.
Primary antibodies including anti-CCN6, anti-Pard6b, anti–
RhoC-GTPase, anti-CDC42, and anti-Rac1/2/3 (Santa Cruz Biotech-
nology, Santa Cruz, CA), anti–β-catenin, anti–atypical protein kinase C
(aPKC; BD Biosciences, San Jose, CA), anti–type I TGF-β receptor
(TβRI), anti-TβRIII (Cell Signaling Technology, Danvers, MA), and
anti–type II TGF-β receptor (TβRII; Fischer, Pittsburgh, PA) were
used at the manufacturers’ recommended dilutions.
Invasion Assay
In vitro invasion assay was performed using 24-well plate Biocoat
Growth Factor Reduced Matrigel Invasion Chambers (BD Bio-
sciences, Bedford, MA) according to the manufacturer’s procedures,
in triplicate.
Human Breast Tissue Samples, Immunohistochemistry,
and Statistical Analyses
A high-density tissue microarray containing 84 primary invasive
carcinomas of the breast developed and characterized by our group
was employed [19]. A 5-μm-thick section was co-immunostained
with rabbit polyclonal anti–CCN6 antibody (Orbigen [Atlanta,
GA], Cat. No. PAB-11197, 1:300) and rabbit polyclonal anti-TβRIII
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(Novus Biologicals [Littleton, CO], Cat. No. 27030002, 1:1500)
following standard biotin-avidin complex technique [19]. The
TβRIII antibody was incubated for 1.5 hours at room temperature.
Antibodies were detected with anti-rabbit Envision+ HRP Labelled
Polymer (DakoCytomation, Carpinteria, CA) for 30 minutes at
room temperature. HRP staining was visualized with the DAB+ Kit
(DakoCytomation). A negative control slide with rabbit IgG was run.
Slides were counterstained in hematoxylin, blued in running tap
water, dehydrated through graded alcohols, cleared in xylene, and
mounted with Permount. Expression of CCN6 and TβRIII was evalu-
ated as either low or high on the basis of intensity of staining and per-
centage of staining cells and following published literature [3,5,20].
Fischer exact test was performed to analyze the association between
TβRIII and CCN6 protein expression. A P value < .05 was considered
statistically significant.
Results
CCN6 KD Is a Key Determinant of the Loss of
Acinar Organization in 3D Cultures
Cultured in 3D, nontumorigenic HME cells provide a robust model
for studying perturbations of the normal acinar architecture and tissue
polarity. Whereas HME cells transduced with the scrambled shRNA
controls form polarized round structures resembling normal mammary
acini, CCN6 KD HME cells form disorganized colonies with loss of
Figure 1. Suppression of CCN6 expression is sufficient to disrupt acinar morphogenesis and polarity. (A) CCN6 KD in nontumorigenic HME
cells led to disruption of acinar organization and formation of disorganized cell clusters with mislocalization of the apical polarity protein
GM130 compared to controls. (B) Immunoblots of HME and MDA-MB-231 cells showed that CCN6 regulates the expression of cell polarity
regulatory proteins. (C) Invasive ability of CCN6-Flag cells and controls (Flag-Vector) in MDA-MB-231 cells was analyzed using the matrigel
invasion assay. Note that stable overexpression of CCN6 decreases the invasiveness of MDA-MB-231 cells compared to controls.
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cell organization and polarity. The loss of apical-basal polarity is
evidenced by detecting the apical polarity marker GM130 (Figure 1A).
Furthermore, CCN6 KD led to altered expression of established regu-
latory proteins of acinar morphogenesis and cell polarity complex pro-
teins β-catenin, Pard6b, aPKC, CDC42, Rac1/2/3, and RhoC-GTPase
(Figures 1B, left, and W1). To validate our results in breast cancer cells,
we ectopically overexpressed CCN6 with Flag tag (CCN6-Flag) in
MDA-MB-231 cells that have low endogenousCCN6 levels andmarked
cellular disorganization. CCN6 overexpression led to a protein expres-
sion profile toward correct cellular organization and polarity (Figure 1B,
right). These protein expression changes induced by ectopic CCN6 were
associated with decreased breast cancer cell invasion (Figure 1C ).
CCN6 Regulates the Expression of TβRIII Protein in
Benign and Breast Cancer Cells
We have recently reported that CCN6 modulates the activity of
the TGF-β superfamily protein BMP4 in breast cells [7]. How-
ever, the possibility that CCN6 may regulate the expression of
the TGF-β receptors has not been considered previously. Quantita-
tive real-time reverse transcription–polymerase chain reaction re-
vealed that CCN6 KD in HME cells increased the mRNA levels
of TβRIII but had no significant effects on the levels of TβRI and
TβRII compared to scrambled controls (Figure 2A). Consistently,
CCN6 KD led to up-regulation of TβRIII protein in HME cells
growing in monolayer and in 3D cultures (Figure 2B). No significant
Figure 2. CCN6 regulates the expression of TβRIII in benign and in breast cancer cells. (A) Quantitative real-time polymerase chain
reaction of TβRI, TβRII, and TβRIII revealed that CCN6 KD in HME cells specifically increases the expression of TβRIII. No significant
effect was observed on the mRNA levels of TβRI or TβRII between HME CCN6 KD and controls. (B) Immunoblots of HME cells with or
without CCN6 KD were grown in monolayers or in 3D. CCN6 KD led to TβRIII up-regulation. (C) Representative confocal images of HME
CCN6 KD and controls stained with anti-TβRIII. DAPI stained the nuclei. (D) Immunoblots of MDA-MB-231 CCN6-Flag cells and controls
(Flag-Vec) demonstrated that stable overexpression of CCN6 reduces TβRIII protein. (E) Representative pictures of primary tumors and
lung metastasis derived from MDA-MB-231 CCN6-Flag and controls, developed previously [7], showed that CCN6 overexpression
decreased TβRIII protein expression in vivo. Black arrow shows normal bronchial epithelium entrapped by the metastatic carcinoma cells.
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effect of CCN6 KD was seen on the protein levels of TβRI and TβRII
(Figure 3, A and C ). IF of cells growing in 3D supported these re-
sults and revealed that TβRIII protein was increased mainly in the
cytoplasm and cellular membranes of CCN6 KDHME cells compared
to controls (Figure 2C ).
We next investigated whether CCN6 regulates the expression of
TβRIII protein in breast cancer cells. Stable CCN6 overexpression
in MDA-MB-231 breast cancer cells was sufficient to reduce TβRIII
protein expression in cell growing as monolayers and in 3D com-
pared to controls (Figure 2D). The effect of CCN6 overexpression
on TβRIII protein was tested in a xenograft model using the same
MDA-MB-231 cells (CCN6-Flag and its control) [7]. As shown in
Figure 2E , TβRIII protein was reduced in CCN6 overexpressing
xenografts and lung metastasis compared to controls.
Inhibition of TβRIII Is Sufficient to Rescue the Invasive,
Disorganized Tissue Morphology and Restore Polarization of
HME CCN6 KD Cells
The strong correlation between CCN6 and TβRIII protein ex-
pression in nontumorigenic and in breast cancer cells led us to
test whether TβRIII inhibition is sufficient to restore the disrupted
tissue architecture and invasive activity induced by CCN6 KD in
HME cells. The expression of TβRIII was downregulated in CCN6
KD cells and controls using the following two complementary
and independent approaches: transient siRNA inhibition and stable
shRNA knockdown.
Western blots show that CCN6 KD induced specific up-regulation
of TβRIII protein but had no effect on the levels of TβRI or TβRII
(Figure 3, A and C ). Furthermore, TβRIII siRNA specifically inhib-
ited TβRIII, with no changes in the protein expression of TβRI or
TβRII (Figure 3A). TβRIII siRNA was sufficient to rescue the en-
hanced invasive capacity of CCN6 KD cells (Figure 3B ). For the
stable down-regulation of TβRIII and CCN6, we constructed HME
cells with CCN6 and TβRIII shRNA double knockdown (CCN6/
TβRIII double KD). We generated two stable clones as well as a
polyclonal pool. As shown in Figure 3C , the shRNA was effective
and specific for TβRIII knockdown. Importantly, TβRIII shRNA res-
cued the invasiveness of CCN6 KD HME cells compared to controls
(Figure 3D).
We next tested the hypothesis that the effects of CCN6 KD on
acinar morphogenesis and polarity observed in 3D may be mediated
Figure 3. Inhibition of TβRIII is sufficient to rescue the invasive activity induced by CCN6 KD. (A) Immunoblots of HME CCN6 KD cells
and controls untreated or treated with TβRIII siRNA. (B) Invasion assay showed that TβRIII siRNA rescued the invasion of CCN6 KD HME
cells. (C) Immunoblots of HMECCN6 KD cells and controls stably transducedwith TβRIII shRNA or control. Two clones and a polyclonal pool
of CCN6/TβRIII double knockdown were tested. (D) Invasion assay showed that down-regulation of TβRIII reversed the invasive ability of
CCN6 KD HME cells.
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through TβRIII up-regulation. In stark contrast with the polarized
and growth-arrested acini formed by HME controls in 3D, CCN6
KD induced the formation of disorganized colonies with loss of the
basal polarity marker α6 integrin and increased cell proliferation
(pHistone3 staining) (Figure 4A). TβRIII knockdown in HME cells
had no effect on acinar polarity and morphogenesis. However, TβRIII
knockdown reversed the disorganized morphology and continued
proliferation of CCN6 KD HME cells toward the formation of cor-
rectly polarized acini in 3D, which recapitulate normal human breast
acini. The percentage of acinar structures increased from 18% in
CCN6 KD cells to more than 80% in CCN6/TβRIII double KD cells,
indicating a rescue of the phenotype (Figure 4B).
Providing further support for the role of CCN6 and TβRIII in
acinar organization, TβRIII knockdown in CCN6 KD cells res-
cued the expression of the basolateral polarity protein E-cadherin
(Figure 5).
Low CCN6 Protein Is Associated with High TβRIII in
Human Invasive Breast Carcinomas
The significance of our novel findings to human breast cancer was
validated by testing the expression of CCN6 and TβRIII in 84 clin-
ical samples of breast cancer arrayed in a tissue microarray [19]. Con-
sistent with previous observations, CCN6 and TβRIII proteins
localized predominantly to the cytoplasm. CCN6 and TβRIII were
scored as high when more than 10% of the cancer cells showed mod-
erate or strong staining and as low when staining was present in 10%
or less of the tumor cells. We found a significant association between
Figure 4. Inhibition of TβRIII expression reverses the disorganized morphology induced by CCN6 KD. (A) Representative phase con-
trast images of cells grown in monolayer or in 3D showed that TβRIII shRNA reversed the disorganized and proliferative morphology
induced by CCN6 KD in HME cells and induced the formation of growth-arrested and polarized acini. Notice the rescue of the basal
polarity marker α6 integrin. (B) The bar graph shows the percentage of single-round acinar structures ± SD obtained by counting
100 structures.
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CCN6 and TβRIII in invasive breast carcinomas. Of the 84 tumors,
54 (64.3%) exhibited an inverse association between CCN6 and
TβRIII proteins. Specifically, 14 (16.7%) had low CCN6 coupled
with high TβRIII expression, and 40 (47.6%) had high CCN6 in
association with low TβRIII (Fisher exact test, P < .041) (Figure 6,
A and B).
Discussion
In the normal breast, epithelial cells are organized around a central
lumen and exhibit apical-basal and lateral polarization [1]. Epithelial
cells maintain close contact to each other through epithelial cell-cell
adhesion proteins that include E-cadherin and β-catenin. In contrast,
invasive breast carcinomas are characterized by disorganized cells
Figure 5. TβRIII knockdown rescues E-cadherin expression due to CCN6 KD. CCN6 KD led to TβRIII up-regulation and decreased expression
of the lateral polarity marker E-cadherin. TβRIII shRNA inhibition was sufficient to rescue E-cadherin protein expression and to restore the
acinar morphology.
Figure 6. CCN6 expression is inversely associated with TβRIII expression in human breast tissue samples. (A) Human breast cancer tissues
(n = 84) immunostained for CCN6 (red) and TβRIII (brown). Tumor case 1 shows an invasive carcinoma with low CCN6 and high TβRIII
protein. Tumor case 2 exhibits high CCN6 and low TβRIII protein. (B) The table shows the distribution of CCN6 and TβRIII. We discovered
a significant inverse association between CCN6 with TβRIII protein in 64% of invasive carcinomas (Fisher exact test, P = .041).
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with aberrant or lack of polarization [21]. Despite advances in the
characterization of normal and invasive carcinoma phenotypes, the
critical regulators of tissue architecture need further investigation.
Using a robust 3D culture model that approximates formation of
human breast acini [18,22], we show that CCN6 down-regulation
leads to disruption of acinar organization and cell polarity in non-
tumorigenic breast epithelial cells. CCN6 KD led to disappearance of
basal, apical, and lateral polarity markers α6 integrin, GM130, and
E-cadherin, respectively. Furthermore, CCN6 KD disrupted the ex-
pression of cell polarity complex proteins Pard6b, CDC42, and aPKC
and of proteins involved in cytoskeletal organization including Rac1/
2/3 and RhoC-GTPase. Supporting the novel function of CCN6 in
maintaining acinar organization, CCN6 overexpression in breast cancer
cells reversed the expression of polarity proteins and inhibited invasion.
From the presented data, CCN6 emerges as a novel regulator of
the TβRIII. Although substantial data exist on the function of TβRI
and TβRII in tumorigenesis, there are limited data on the function of
TβRIII. Recent studies have shown that TβRIII is an important reg-
ulator of cancer cell growth and invasion, with context-dependent
roles in cancer progression [9,12]. While TβRIII has been demon-
strated to be lost or decreased in several cancers [13,14,16] suggest-
ing a tumor suppressor function, other studies have shown that it is
upregulated in colon cancer where its increased expression induced cell
migration and anchorage-independent capacity [17]. The possibility
that CCN6 may regulate the expression and function of the TβRIII
has not been investigated previously. Our data show that CCN6
down-regulation led to overexpression of TβRIII in benign breast cells,
whereas CCN6 overexpression in breast cancer cells inhibited TβRIII
compared to controls. By using independent and complementary strat-
egies including transient siRNA and stable shRNA interference, we
provide evidence that the effects of CCN6 KD in coordinating the
invasive and disorganized phenotype require up-regulation of TβRIII.
Furthermore, TβRIII knockdown was sufficient to rescue the E-cadherin
down-regulation due to CCN6 KD in HME cells.
The in vivo relevance of the novel mechanistic link between CCN6
and TβRIII proteins was determined by testing their expression in
xenografts and human tissue samples. In xenograft samples, CCN6 over-
expression in MDA-MB-231 cells decreased the levels of TβRIII pro-
tein in primary and metastatic tumors. In human breast cancer tissue
samples, an inverse association between CCN6 and TβRIII protein
expression was observed in 54 of 84 (64.3%) of invasive carcinomas.
In conclusion, our results demonstrate that CCN6 is a novel regulator
of breast tissue architecture. CCN6 down-regulation in nontumorigenic
breast cells disrupts cell polarization and acinar formation, leading to
a disorganized phenotype with invasive properties. Our results enable
us to pinpoint one novel mechanism that involves CCN6-mediated
regulation of TβRIII. From a clinical perspective, the role of CCN6
in maintaining normal acinar morphology through TβRIII is of par-
ticular interest, as it may offer new targets to prevent tissue invasion.
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Figure W1. CCN6 KD in HME cells leads to increased RhoC protein
expression in cells cultured in 3D. Representative confocal images
of HME CCN6 KD and controls stained with anti-RhoC are shown.
DAPI was used to stain the nuclei.
